.svg){kind=small}
Due to web security any ideas and or information sent to RP via this Web site will be deemed not to be confidential and by sending information, you are granting RP unrestricted and irrevocable licence to use, reproduce, display, perform, modify, transmit and distribute. However RP will not release your name or otherwise publicise the fact that information was sent unless RP obtains your permission to do so or if RP is required to do so by law.
Please note that RP does not endorse any other Web sites accessed via this site or accepts any responsibility for the content or accuracy of information contained on that site. In no event will RP be liable to any party for any damages arising from any use of or access to this Web site.
Disclaimer
This Web site has been created solely for the purpose of providing information about services available from Richmond Pharmacology (RP). The site has been compiled in good faith from information available at the time and is therefore subject to change at any time and without notification.
-min.jpg)
.jpg)
Latest news
Von Willebrand Disease – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol
April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read moreFirst patient enrolled in telehealth study, the Pathway Study
February 25, 2025
The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and the National Amyloidosis Centre and aims...
Read moreEvents
CRISPR Medicine 2025: Unlocking Gene-Editing Potential
April 7–11
Exploring advancements shaping the future of healthcare.
View event
